GlycoNet Announces Two New Members on the Board of Directors
- Drs. Kaley Wilson and Elizabeth Nanak bring their insight to GlycoNet’s Board of Directors
GlycoNet is pleased to announce two new members have joined its Board of Directors: Drs. Kaley Wilson and Elizabeth Nanak. As members of the Board, they will be responsible for the overall stewardship of GlycoNet, including strategic planning and board governance.
Dr. Kaley Wilson is currently a Principal and the Director of Business Development at Quark Venture, a Vancouver-based venture capital group that invests globally in health science. Investing out of the Global Health Sciences Funds, Dr. Wilson works closely with Quark’s Investment Committee to identify and diligence potential investment opportunities. From January 2018 until September 2019, Dr. Wilson was also the interim CEO of ARTMS Products Inc., a global leader in the development of disruptive medical isotope production technologies. Following its seed financing, Dr. Wilson joined ARTMS to help grow the company and to implement a global sales and marketing strategy and to initiate the company’s Series A raise of $19M USD, which was secured in May 2020. Following her time as interim CEO, Dr. Wilson oversaw ARTMS’ acquisition by Telix Pharmaceuticals in 2024 as a Director on the Board. Dr. Wilson is also the Chair of GlycoNet’s Commercialization Committee, a former member of the Nanomedicines Innovation Network’s (NMIN) Research Management Committee and a Director on the Boards of Microbion, SeraGene, NZ Technologies and Crohn’s and Colitis Canada. Dr. Wilson was previously a Director on the Boards of Canary Medical, ARTMS, IOME and is also currently an Observer on the Board of Oculogica.
“I am delighted to welcome our new Board members Dr. Wilson and Dr. Nanak,” said Karimah Es Sabar, Chair of the Board of Directors. “Their unique experiences and perspectives will undoubtedly add value to GlycoNet and strengthen the organization as we move forward. We look forward to their contributions and insights.”
Dr. Elizabeth Nanak is GlycoNet’s Chief Executive Officer. Dr. Nanak has been involved with GlycoNet since its inception and prior to becoming CEO in 2020, she served as the Executive Director. She also contributed to growing GlycoNet’s precursor, the Alberta Glycomics Centre, as Associate Director, Business during 2007–2015. Dr. Nanak has over 20 years of experience with complex multi-stakeholder programs and has been instrumental in securing more than $160M in public and private funding.
“I’m pleased to join our Board members who bring a diverse range of expertise and knowledge across the areas of One Health, commercialization and entrepreneurship, and socio-economic development to drive community impact,” says CEO Elizabeth Nanak. “I look forward to working closely with other members of the Board and to seeing what we will accomplish together.”
Original source here.